CN102625830B - 间充质干细胞分化 - Google Patents

间充质干细胞分化 Download PDF

Info

Publication number
CN102625830B
CN102625830B CN201080031985.4A CN201080031985A CN102625830B CN 102625830 B CN102625830 B CN 102625830B CN 201080031985 A CN201080031985 A CN 201080031985A CN 102625830 B CN102625830 B CN 102625830B
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
angptl3
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080031985.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102625830A (zh
Inventor
K·约翰逊
L·詹宁斯
P·舒尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis International Pharmaceutical Ltd
Novartis AG
Scripps Research Institute
Original Assignee
IRM LLC
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102625830(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IRM LLC, Novartis AG, Scripps Research Institute filed Critical IRM LLC
Priority to CN201610077451.4A priority Critical patent/CN105601728B/zh
Publication of CN102625830A publication Critical patent/CN102625830A/zh
Application granted granted Critical
Publication of CN102625830B publication Critical patent/CN102625830B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080031985.4A 2009-07-14 2010-07-13 间充质干细胞分化 Active CN102625830B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610077451.4A CN105601728B (zh) 2009-07-14 2010-07-13 间充质干细胞分化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14
US61/225,293 2009-07-14
PCT/US2010/041850 WO2011008773A2 (en) 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610077451.4A Division CN105601728B (zh) 2009-07-14 2010-07-13 间充质干细胞分化

Publications (2)

Publication Number Publication Date
CN102625830A CN102625830A (zh) 2012-08-01
CN102625830B true CN102625830B (zh) 2016-03-02

Family

ID=43450138

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080031985.4A Active CN102625830B (zh) 2009-07-14 2010-07-13 间充质干细胞分化
CN201610077451.4A Active CN105601728B (zh) 2009-07-14 2010-07-13 间充质干细胞分化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610077451.4A Active CN105601728B (zh) 2009-07-14 2010-07-13 间充质干细胞分化

Country Status (30)

Country Link
US (4) US9139633B2 (enExample)
EP (1) EP2453921B1 (enExample)
JP (1) JP5602850B2 (enExample)
KR (3) KR20160015403A (enExample)
CN (2) CN102625830B (enExample)
AU (1) AU2010273570B2 (enExample)
BR (1) BR112012000914B8 (enExample)
CA (1) CA2767826C (enExample)
CL (1) CL2012000091A1 (enExample)
CO (1) CO6491059A2 (enExample)
CR (1) CR20120024A (enExample)
CU (1) CU24042B1 (enExample)
EA (1) EA023073B1 (enExample)
EC (1) ECSP12011604A (enExample)
ES (1) ES2541217T3 (enExample)
GT (1) GT201200011A (enExample)
IL (2) IL217383A (enExample)
IN (1) IN2012DN00572A (enExample)
MA (1) MA33423B1 (enExample)
MX (1) MX2012000707A (enExample)
MY (1) MY160951A (enExample)
NZ (1) NZ597306A (enExample)
PE (2) PE20160507A1 (enExample)
PL (1) PL2453921T3 (enExample)
PT (1) PT2453921E (enExample)
SG (1) SG177318A1 (enExample)
TN (1) TN2011000655A1 (enExample)
UA (1) UA104031C2 (enExample)
WO (1) WO2011008773A2 (enExample)
ZA (1) ZA201200078B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2453921T3 (pl) * 2009-07-14 2015-11-30 Scripps Research Inst Różnicowanie mezenchymalnych komórek macierzystych
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
EP2779649A4 (en) 2011-11-08 2016-01-06 Korea Electronics Telecomm METHOD AND DEVICE FOR THE JOINT USE OF A CANDIDATE LIST
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
PT2864360T (pt) * 2012-06-25 2018-01-05 The Brigham And Women`S Hospital Inc Terapêuticas dirigidas ao alvo
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
KR102283996B1 (ko) 2013-03-15 2021-07-29 더 스크립스 리서치 인스티튜트 연골형성의 유도를 위한 화합물 및 방법
EP3143026B1 (en) 2014-05-13 2024-07-10 Novartis AG Compounds and compositions for inducing chondrogenesis
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
KR102456731B1 (ko) 2016-03-03 2022-10-24 리제너론 파아마슈티컬스, 인크. Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
CN117860868A (zh) * 2016-11-14 2024-04-12 诺华股份有限公司 用于治疗软骨损伤和关节炎的方法和组合物
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
CN113015735B (zh) 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083851A2 (en) * 2001-04-10 2002-10-24 Genvec, Inc. Vegf fusion proteins
CN1615440A (zh) * 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
WO2001005972A1 (en) * 1999-07-20 2001-01-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO1999058660A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
WO1999067382A2 (en) 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
KR20010104373A (ko) 1999-03-08 2001-11-24 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040249141A1 (en) * 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
ES2304401T3 (es) * 2000-10-16 2008-10-16 Genentech, Inc. Metodos de tratamiento que utilizan polipeptidos wisp.
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
MXPA05002620A (es) * 2002-09-09 2005-05-05 Nektar Therapeutics Al Corp Alcanales polimericos solubles en agua.
ATE488588T1 (de) * 2003-03-10 2010-12-15 Japan Science & Tech Agency Verfahren zur kennzeichnung mesenchymaler stammzellen unter verwendung verschiedener marker
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
JP5269411B2 (ja) * 2004-06-21 2013-08-21 ザ クリーブランド クリニック ファウンデーション 幹細胞をホーミングさせるためのｃｃｒリガンド
JP2008532516A (ja) 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
WO2008137641A2 (en) * 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
PL2453921T3 (pl) * 2009-07-14 2015-11-30 Scripps Research Inst Różnicowanie mezenchymalnych komórek macierzystych
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083851A2 (en) * 2001-04-10 2002-10-24 Genvec, Inc. Vegf fusion proteins
CN1615440A (zh) * 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法

Also Published As

Publication number Publication date
CA2767826A1 (en) 2011-01-20
EP2453921B1 (en) 2015-05-27
HK1164169A1 (en) 2012-09-21
WO2011008773A3 (en) 2011-08-25
IL217383A (en) 2016-08-31
MY160951A (en) 2017-03-31
ZA201200078B (en) 2013-01-30
CL2012000091A1 (es) 2012-10-26
PL2453921T3 (pl) 2015-11-30
KR20180000337A (ko) 2018-01-02
CN105601728B (zh) 2020-01-10
CN105601728A (zh) 2016-05-25
MX2012000707A (es) 2012-03-21
TN2011000655A1 (en) 2013-05-24
JP5602850B2 (ja) 2014-10-08
CO6491059A2 (es) 2012-07-31
EA023073B1 (ru) 2016-04-29
BR112012000914A2 (pt) 2017-08-08
US9139633B2 (en) 2015-09-22
UA104031C2 (uk) 2013-12-25
US10064918B2 (en) 2018-09-04
NZ597306A (en) 2014-03-28
GT201200011A (es) 2013-12-10
CA2767826C (en) 2015-11-24
AU2010273570A1 (en) 2012-02-02
ECSP12011604A (es) 2012-06-29
SG177318A1 (en) 2012-03-29
BR112012000914A8 (pt) 2017-12-19
US20160213748A1 (en) 2016-07-28
KR20160015403A (ko) 2016-02-12
IN2012DN00572A (enExample) 2015-06-12
IL217383A0 (en) 2012-02-29
BR112012000914B1 (pt) 2021-04-06
PT2453921E (pt) 2015-09-25
CU20120007A7 (es) 2013-02-26
EP2453921A4 (en) 2012-12-19
US10555990B2 (en) 2020-02-11
BR112012000914B8 (pt) 2021-05-25
US11241482B2 (en) 2022-02-08
PE20120570A1 (es) 2012-05-19
AU2010273570B2 (en) 2014-07-03
US20190000922A1 (en) 2019-01-03
MA33423B1 (fr) 2012-07-03
US20200108122A1 (en) 2020-04-09
CR20120024A (es) 2012-06-11
CN102625830A (zh) 2012-08-01
US20120177644A1 (en) 2012-07-12
WO2011008773A2 (en) 2011-01-20
KR20120029472A (ko) 2012-03-26
IL247310B (en) 2018-04-30
EP2453921A2 (en) 2012-05-23
CU24042B1 (es) 2014-11-27
JP2012533549A (ja) 2012-12-27
KR101590834B1 (ko) 2016-02-12
ES2541217T3 (es) 2015-07-16
EA201200118A1 (ru) 2012-09-28
PE20160507A1 (es) 2016-05-20

Similar Documents

Publication Publication Date Title
CN102625830B (zh) 间充质干细胞分化
US10328126B2 (en) Peptides and compositions for treatment of joint damage
US20220402987A1 (en) Peptides and compositions for treatment of joint damage
HK40038214A (en) Peptides and compositions for treatment of joint damage
HK1164169B (en) Mesenchymal stem cell differentiation
HK1260928A1 (en) Peptides and compositions for treatment of joint damage
HK1214754B (en) Peptides and compositions for treatment of joint damage

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160105

Address after: American California

Applicant after: THE SCRIPPS Research Institute

Applicant after: NOVARTIS AG

Address before: American California

Applicant before: THE SCRIPPS Research Institute

Applicant before: Novartis international pharmaceuticals Ltd.

Effective date of registration: 20160105

Address after: American California

Applicant after: THE SCRIPPS Research Institute

Applicant after: Novartis international pharmaceuticals Ltd.

Address before: American California

Applicant before: THE SCRIPPS Research Institute

Applicant before: IRM LLC

C14 Grant of patent or utility model
GR01 Patent grant